HMN-214

CAS : 173529-46-9

Ref. 3D-FH170580

Informations sur le produit

• Nom: HMN-214
• Synonymes: (E)-4-[2-[2-[N-Acetyl-N-[(p-methoxyphenyl)sulfonyl]amino]phenyl]ethenyl]pyridine 1-oxide, Acetamide, N-[(4-methoxyphenyl)sulfonyl]-N-[2-[(1E)-2-(1-oxido-4-pyridinyl)ethenyl]phenyl]-, Acetamide, N-[(4-methoxyphenyl)sulfonyl]-N-[2-[2-(1-oxido-4-pyridinyl)ethenyl]phenyl]-, (E)-, Hmn-214, Ivx 214, N-[(4-Methoxyphenyl)sulfonyl]-N-[2-[(1E)-2-(1-oxido-4-pyridinyl)ethenyl]phenyl]acetamide

Description

HMN-214 is a novel oral prodrug that is being developed as a single agent therapy for the treatment of cancer. HMN-214 is a prodrug of the natural product dihydromyricetin, which inhibits mitochondrial complex I and II. HMN-214 has shown potent antitumor activity in tumor xenografts and demonstrated safety profile in vivo. The drug also induces cancer cell death via a mechanism that involves inhibition of kinase domain phosphorylation, leading to apoptosis induction. HMN-214 has been tested in vitro and in vivo for pharmacokinetics and gene expression profiling with promising results.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 424.47 g/mol
• Formule: C₂₂H₂₀N₂O₅S
• Degré de pureté: Min. 95%